Delft/Kaiseraugst, 13 June 2005
Recent research by DSM has confirmed the superior efficacy, stability and
survival of DSM`s probiotic Lactobacillus acidophilus LAFTI® L10. With the
probiotic activity of many supplements significantly reduced by the time the
capsule reaches the gastro-intestinal tract – the only place that really
matters – the proven gastro-intestinal survival of LAFTI® L10 will benefit
both Dietary Supplement manufacturers and consumers.
‘’Probiotic success depends on three key factors - efficacy of the probiotic
strain selected, stability of the probiotic in the dietary supplement and
survival in the human gastro-intestinal tract,“ comments Nelleke van Oorschot,
technical service officer of DSM Food Specialties. “The efficacy of the LAFTI®
strain and its survival in the gastro-intestinal tract have already been
demonstrated in several trials. With the latest results from stability trials,
we are in a position to provide manufacturers with clear and transparent
stability statements which define what residual cell count can be expected
after storage at typical temperatures.”
DSM has dedicated considerable resource to developing the LAFTI® range and
more beneficial effects are investigated in on-going human clinical trials.
The three LAFTI® strains (Lactobacillus acidophilus LAFTI® L10,
Bifidobacterium lactis LAFTI® B94 and Lactobacillus casei LAFTI® L26) have
been selected for their positive probiotic effect to the consumer, good
stability and excellent survival in the gastro-intestinal tract. They also
deliver a high level of colony forming units per gram and promise an excellent
shelf life, making them a safe, scientifically-backed option for both
manufacturers and consumers.
Currently, LAFTI® L10 for Dietary Supplements is available via DSM Nutritional
Products. LAFTI® L10 for Food is available via DSM Food Specialties. For
further product information please visit:
www.lafti.com.
